A prospective phase II trial of docetaxel-samarium in patients with hormone-refractory advanced prostate cancer who achieve a response or a stabilization to docetaxel-estramustine
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2013
At a glance
- Drugs Docetaxel (Primary) ; Samarium-153-SM-lexidronam (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 06 Jun 2007 Interim results have been reported.
- 01 Nov 2005 New trial record.